Click here to unsubscribe from our email list or mark as SPAM .
Please add us to your address book or whitelist us. Directions for whitelisting are here.

A monumental stride in neurological diagnostics has emerged as the US Food and Drug Administration has formally sanctioned the marketing of a novel blood-based diagnostic tool designed to support the identification of Alzheimer’s disease in its formative stages. This advancement marks the nation’s first federally greenlit blood assay with this capacity.

You opted in to receive these emails when you requested information or entered one of our contests. You can Manage Subcription here if you do not want to receive these emails any longer. To help make sure we make it into your inbox, add [email protected] to your address book.